(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.54%.
Aligos Therapeutics's earnings in 2026 is -$75,962,000.On average, 10 Wall Street analysts forecast ALGS's earnings for 2026 to be -$82,531,825, with the lowest ALGS earnings forecast at -$102,565,616, and the highest ALGS earnings forecast at -$56,912,902. On average, 10 Wall Street analysts forecast ALGS's earnings for 2027 to be -$68,455,343, with the lowest ALGS earnings forecast at -$87,878,416, and the highest ALGS earnings forecast at -$36,455,730.
In 2028, ALGS is forecast to generate -$31,189,069 in earnings, with the lowest earnings forecast at -$61,074,275 and the highest earnings forecast at $52,585,423.